AbbVie (ABBV) Research & Development (2012 - 2026)

AbbVie has disclosed Research & Development across 15 years of filings, most recently posting $2.5 billion for Q1 2026.

• In Q1 2026, Research & Development rose 19.59% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $9.5 billion (down 26.46% YoY), while the FY2025 annual figure was $9.1 billion, down 28.89% from the prior year.
• Research & Development declined to $2.5 billion in Q1 2026, from $2.6 billion in the prior quarter.
• Over the last five years, Research & Development for ABBV reached as high as $6.8 billion in Q4 2024 and fell as low as $1.5 billion in Q1 2022.
• The 5-year median for Research & Development is $1.9 billion (2024), against an average of $2.3 billion.
• Annual changes were most pronounced in 2024 — Research & Development soared 251.53% — and 2025, when it tumbled 61.93%.
• A 5-year view of Research & Development shows it stood at $1.8 billion in 2022, then advanced by 7.65% to $1.9 billion in 2023, then soared by 251.53% to $6.8 billion in 2024, then plunged by 61.93% to $2.6 billion in 2025, then retreated by 4.15% to $2.5 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.5 billion, $2.6 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.